Life Sciences

Showing 481–490 of 506 results

Sort by popularity Sort by average rating Sort by latest Sort by price: low to high Sort by price: high to low

• 

  Lipid-Lowering Drugs Market in China 2021

  The lipid-lowering drugs market in China in terms of revenue is set to grow by US$ 5 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 11.4% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the lipid-lowering drugs market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Rosuvastatin Market in China 2021

  The rosuvastatin market in China in terms of revenue is set to grow by US$ 641 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 8.3% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the rosuvastatin market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Cardiovascular Pharmaceutical Market in China 2021

  The cardiovascular pharmaceutical market in China in terms of revenue is set to grow by US$ 7 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 3.3% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the cardiovascular pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Anti-Infective Pharmaceutical Market in China 2021

  The anti-infective pharmaceutical market in China in terms of revenue is set to grow by US$ 6 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 2.8% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the anti-infective pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Carbapenem Drug Market in China 2021

  The carbapenem drug market in China in terms of revenue is set to grow by US$ 493 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 5.6% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the carbapenem drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Biapenem Pharmaceutical Market in China 2021

  In terms of revenue, the biapenem pharmaceutical market in China is projected to grow at a compound annual growth rate (CAGR) of 3.2% over the analysis period of 2021 to 2027, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the biapenem pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Mono-Ingredient Amoxicillin Pharmaceutical Market in China 2021

  The mono-ingredient amoxicillin pharmaceutical market in China in terms of revenue is set to grow by US$ 924 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 3.1% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the mono-ingredient amoxicillin pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  ADCs for HER2-Expressing Breast Cancer Market in China 2021

  The ADCs for HER2-expressing breast cancer market in China in terms of revenue is set to grow by US$ 373 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 96.8% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the ADCs for HER2-expressing breast cancer market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Urothelial Carcinoma (UC) Drug Market in China 2021

  The urothelial carcinoma (UC) drug market in China in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 27.6% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the urothelial carcinoma (UC) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Gastric Cancer Drug Market in China 2021

  The gastric cancer drug market in China in terms of revenue is set to grow by US$ 4 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 10.3% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the gastric cancer drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450